Biotech
Nutriband Reports 51% Revenue Growth, Advances Abuse-Deterrent Fentanyl Patch Toward FDA Approval
Nutriband Inc. achieved significant revenue growth and strengthened its financial position to advance AVERSA Fentanyl, potentially becoming the first global abuse-deterrent transdermal fentanyl product with estimated peak annual sales of $80-200 million.
Quantum BioPharma Receives BUY Rating with $45 Price Target from Kingswood Capital
Quantum BioPharma Ltd. received an independent BUY rating and $45 price target from Kingswood Capital Partners, signaling strong analyst confidence in the company's neurodegenerative disease treatment pipeline and future commercial potential.
Oncotelic Therapeutics Highlights CEO's Track Record and Clinical Pipeline Advancements
Oncotelic Therapeutics showcases CEO Dr. Vuong Trieu's substantial patent portfolio and successful drug development history while updating progress on its oncology and immunotherapy pipeline.
ABVC BioPharma Subsidiary Receives $230,000 Milestone Payment in Botanical Drug Partnership
BioLite, an ABVC BioPharma subsidiary, received a $230,000 milestone payment from AiBtl BioPharma, advancing their collaboration on botanical-derived treatments for depression and ADHD that could generate up to $667 million in total value.
Lantern Pharma Advances Oncology Pipeline with AI-Driven Clinical Progress and Extended Financial Runway
Lantern Pharma reports significant clinical trial advancements and AI platform enhancements while maintaining strong financial discipline, positioning the company for continued oncology drug development through mid-2026.
ABVC BioPharma Receives $100,000 Milestone Payment in Vitargus Licensing Deal
ABVC BioPharma's latest milestone payment from ForSeeCon Eye Corporation strengthens a licensing agreement potentially worth $63.5 million for Vitargus®, positioning the company to capitalize on the multi-billion dollar global vitreous substitute market.
Calidi Biotherapeutics Prices $6 Million Public Offering to Advance Clinical-Stage Cancer Therapies
Calidi Biotherapeutics has priced a $6 million public offering to fund development of its Redtail platform, which uses engineered oncolytic viruses to deliver genetic medicines to metastatic cancer sites, addressing high unmet medical needs in oncology.
Bank of America Downgrades Novavax to Underperform Citing Long-Term Growth Concerns
Bank of America downgraded Novavax to Underperform due to concerns about the vaccine maker's sustainable growth prospects amid shifting COVID-19 variants and heightened FDA regulatory requirements.
ABVC BioPharma, Inc. Achieves Significant Asset Growth and Secures Licensing Revenue in Q2 2025
ABVC BioPharma, Inc. reports a 103% year-over-year increase in total assets and secures $350K in post-quarter licensing revenue, highlighting strategic growth and operational efficiency.
ARTBIO Strengthens Leadership with Strategic Board Appointments to Advance Cancer Therapies
ARTBIO enhances its board with four industry veterans to propel its innovative alpha radioligand therapies, marking a pivotal step in its mission to revolutionize cancer treatment.
EnPlusOne Biosciences Aims to Revolutionize RNA Therapeutics with Enzymatic Synthesis
EnPlusOne Biosciences, under the leadership of CEO Clare Murray Ph.D., is pioneering an enzymatic approach to RNA synthesis, addressing the limitations of current methods and paving the way for scalable, pure, and environmentally friendly RNA therapeutics.
XOMA Royalty to Acquire LAVA Therapeutics in a Deal Worth Up to $1.24 Per Share Plus Contingent Value Rights
XOMA Royalty Corporation's acquisition of LAVA Therapeutics for up to $1.24 per share plus contingent value rights marks a significant move in the biotech sector, promising to benefit shareholders and advance innovative cancer treatments.
Soligenix Inc. Achieves Significant Milestone in Phase 2a Study for Behçet’s Disease Treatment
Soligenix Inc. reports promising results from its Phase 2a study of SGX945 for Behçet’s Disease, showing potential to address unmet medical needs in inflammatory conditions.
Branded Legacy, Inc. to Acquire Bio-Legacy Evaluative Group, Expanding into Intranasal Drug Delivery Market
Branded Legacy, Inc. (OTC: BLEG) has signed a Letter of Intent to acquire Bio-Legacy Evaluative Group, marking a strategic expansion into the intranasal drug delivery sector with a focus on addiction treatments and vaccine accessibility.
Fifty 1 Labs, Inc. (OTC: FITY) Showcases AI-Driven Growth Strategy in Virtual Shareholder Teleconference
Fifty 1 Labs, Inc. (OTC: FITY) highlighted its AI-driven strategy for the functional medicine and biotech sectors during a virtual teleconference, emphasizing significant market opportunities and shareholder value creation.
Fifty 1 Labs and UAV Corp to Host Virtual Shareholder Teleconference with Nobel Laureate Dr. James Orbinski
Fifty 1 Labs and UAV Corp announce a virtual shareholder teleconference featuring Nobel Laureate Dr. James Orbinski, highlighting strategic initiatives in AI-driven health solutions and biotech acquisitions.
ABVC BioPharma Achieves $100,000 Licensing Milestone with ForSeeCon, Enhancing Ophthalmology Focus
ABVC BioPharma's recent $100,000 milestone payment from ForSeeCon Eye Corporation underscores the growing commercial interest in its ophthalmology solutions, particularly Vitargus®, and strengthens its position in the global eye care market.
Nutriband Inc. Added to Four Russell Indexes, Highlighting Market Recognition and Growth Potential
Nutriband Inc.'s inclusion in four Russell indexes underscores the market's recognition of its AVERSA pipeline and its potential impact on the pharmaceutical industry.
Scinai Immunotherapeutics Ltd. Highlights PC111 Breakthrough Following Top Italian Dermatology Award
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) celebrates Dr. Roberta Lotti's award-winning research on PC111, a promising treatment for pemphigus vulgaris, underscoring its potential as a non-immunosuppressive therapy for autoimmune skin conditions.
Nutriband Inc. (NASDAQ: NTRB) Sees Price Target Increase to $15 After AVERSA Fentanyl Manufacturing Achievement
Nutriband Inc.'s price target was raised to $15 following the successful commercial manufacturing and scale-up of its AVERSA Fentanyl abuse-deterrent transdermal patch, marking a significant step towards clinical trials and potential market entry.
PolyPid Secures $26.7 Million Funding, Advances Toward FDA Approval with Promising D-PLEX₁₀₀
PolyPid Ltd. has secured $26.7 million in funding following successful Phase 3 trial results for its surgical infection prevention technology, D-PLEX₁₀₀, positioning the company for FDA approval and significant market impact.
Stonegate Capital Partners Initiates Coverage on Cingulate Inc. with Focus on ADHD Treatment Innovation
Stonegate Capital Partners has begun coverage on Cingulate Inc., highlighting the company's progress with CTx-1301, a potential breakthrough in ADHD treatment, targeting a significant market opportunity.
Medicus Pharma Ltd. (NASDAQ: MDCX) Strategically Positions Itself in the Rapidly Growing $5 Trillion Biotech Market
Medicus Pharma Ltd. is leveraging the aging global population and technological advancements in biopharma to address chronic diseases, positioning itself for significant growth in the $5 trillion biotech market by 2034.
Aditxt Inc. Strengthens Board with Appointment of Evofem CEO Saundra Pelletier
Aditxt Inc. (NASDAQ: ADTX) has appointed Saundra Pelletier, CEO of Evofem Biosciences, to its Board of Directors, signaling a strategic focus on women's health and commercialization efforts.
Scinai Immunotherapeutics Clears Italian Regulatory Hurdle for Pincell Acquisition
Scinai Immunotherapeutics Ltd. has received Italian regulatory approval to proceed with its option to acquire Pincell S.r.l., a move that could significantly expand its inflammation and immunology pipeline with Pincell's promising monoclonal antibody, PC111.
Catalio Capital Invests in $130 Million Series B Funding for GlycoEra to Advance Autoimmune Disease Treatments
Catalio Capital Management has participated in a $130 million Series B funding round for GlycoEra AG, a Swiss biotech firm, to develop innovative treatments for autoimmune diseases, marking a significant step forward in life sciences investment and healthcare innovation.
GlycoEra Secures $130 Million in Series B Funding to Advance Autoimmune Disease Treatments
GlycoEra AG, a Swiss biotech firm, has raised $130 million in a Series B funding round led by Novo Holdings, with participation from several new and existing investors, to advance its innovative treatments for autoimmune diseases.
Tenpoint Therapeutics Strengthens Leadership Team with Appointment of Melissa Epperly as CFO
Tenpoint Therapeutics appoints Melissa Epperly as CFO to lead financial strategy and operations, marking a pivotal step towards the potential U.S. launch of its innovative treatment for presbyopia, BRIMOCHOLPF.
Nutriband Reports Record Q1 Revenue, Advances Abuse-Deterrent Fentanyl Patch Development
Nutriband Inc. reported a 63% year-over-year revenue increase in Q1, driven by expanded kinesiology tape production and retail presence, while simultaneously progressing its AVERSA Fentanyl patch development through a strategic partnership with Kindeva Drug Delivery.
Scinai Immunotherapeutics Reports Revenue Growth and Narrowing Losses in Q1 2025
Scinai Immunotherapeutics demonstrates financial resilience with increased revenue from CDMO contracts and reduced net losses, signaling potential strategic pivots in its business model.